| Disease Specific Interactions between Host Protein and DME (HOSPPI) |
| ICD Disease Classification Healthy |
| ICD-11: Healthy |
Click to Show/Hide the Full List of HOSPPI: 4 HOSPPI
|
| Oligomerization |
| Cytochrome b5 (CYB5A) |
Health |
Heterooligomer |
| Uniprot ID |
|
| Interaction Name |
CYB5A-CYP3A5 heterooligomerization |
[1], [2] |
| Studied Cell Lines |
DLPC vesicles |
| Description |
Cytochrome b5 (CYB5A) is reported to heterooligomerize with the CYP3A5 protein, which leads to an increased activity of the drug-metabolizing enzyme Cytochrome P450 3A5. As a result, the interaction between CYB5A and CYP3A5 can facilitate the drug-metabolizing process of Cytochrome P450 3A5. |
| Cytochrome P450 2E1 (CYP2E1) |
Health |
Heterooligomer |
| Uniprot ID |
|
| Interaction Name |
CYP2E1-CYP3A5 heterooligomerization |
[3] |
| Studied Cell Lines |
Insect cell microsomes |
| Affected Substrate(s): |
7-Benzyloxyquinoline (Metabolic product: 7-BQ O-debenzylation)
|
| Description |
Cytochrome P450 2E1 (CYP2E1) is reported to heterooligomerize with the CYP3A5 protein, which leads to a slight effect on the activity of drug-metabolizing enzyme Cytochrome P450 3A5. As a result, the interaction between CYP2E1 and CYP3A5 slightly affects the drug-metabolizing process of Cytochrome P450 3A5. |
| Mutated NADPH-CYP450 reductase (mPOR) |
Health |
Heterooligomer |
| Uniprot ID |
|
| Interaction Name |
mPOR-CYP3A5 heterooligomerization |
[4], [5] |
| Studied Cell Lines |
Escherichia coli BL21(DE3) cell line |
| Affected Substrate(s): |
Tacrolimus
|
| Description |
Mutated NADPH-CYP450 reductase (mPOR) is reported to heterooligomerize with the CYP3A5 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Cytochrome P450 3A5. As a result, the interaction mutant type between mPOR and CYP3A5 can inhibit the drug-metabolizing process of Cytochrome P450 3A5. |
| NADPH-CYP450 reductase (POR) |
Health |
Heterooligomer |
| Uniprot ID |
|
| Interaction Name |
POR-CYP3A5 heterooligomerization |
[4], [5] |
| Studied Cell Lines |
Reconstituted liposomes |
| Affected Substrate(s): |
Tacrolimus
|
| Description |
NADPH-CYP450 reductase (POR) is reported to heterooligomerize with the CYP3A5 protein, which leads to activation of the drug-metabolizing enzyme Cytochrome P450 3A5. As a result, the interaction between POR and CYP3A5 can activate the drug-metabolizing process of Cytochrome P450 3A5. |
| ICD Disease Classification 02 Neoplasms |
| ICD-11: 2C12 Liver cancer |
Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI
|
| DNA methylation |
| DNA methyltransferase (DNMT) |
Liver cancer |
Significant hypermethylation |
| Uniprot ID |
|
| Interaction Name |
DNMT-CYP3A5 interaction |
[6] |
| Studied Cell Lines |
Live tissue |
| Description |
DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP3A5 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Cytochrome P450 3A5. As a result, the interaction between DNMT and CYP3A5 can significantly affect the drug-metabolizing process of Cytochrome P450 3A5. |
|
|
|
|
|
|
